Drug: Inotuzumab ozogamicin (Besponsa, Pfizer)
Status: Approved for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Significant Information:
- Inotuzumab ozogamicin is thought to work by binding to B-cell ALL cancer cells that express the CD22 antigen, blocking the growth of cancerous cells.
- 326 patients with relapsed or refractory B-cell ALL who had received 1 or 2 prior treatments were randomly assigned to receive inotuzumab ozogamicin